MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ
50.68
+0.48
+0.95%
Opening 10:04 10/03 EDT
OPEN
50.73
PREV CLOSE
50.20
HIGH
50.90
LOW
49.69
VOLUME
46.80K
TURNOVER
2.06M
52 WEEK HIGH
55.58
52 WEEK LOW
25.01
MARKET CAP
3.63B
P/E (TTM)
-6.4714
1D
5D
1M
3M
1Y
5Y
Investing in PTC Therapeutics (NASDAQ:PTCT) five years ago would have delivered you a 173% gain
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Simply Wall St. · 09/20 15:54
Jefferies Initiates Coverage On PTC Therapeutics with Buy Rating, Announces Price Target of $62
Jefferies analyst Kelly Shi initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Buy rating and announces Price Target of $62.
Benzinga · 09/12 10:10
Jefferies Initiates PTC Therapeutics at Buy With $62 Price Target
Jefferies Initiates PTC Therapeutics at Buy With $62 Price Target
MT Newswires · 09/12 07:02
Analyst Ratings for PTC Therapeutics
Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter:
Benzinga · 09/09 14:40
Morgan Stanley Initiates Coverage On PTC Therapeutics with Equal-Weight Rating, Announces Price Target of $54
Morgan Stanley analyst Andrew Galler initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Equal-Weight rating and announces Price Target of $54.
Benzinga · 09/09 12:05
Morgan Stanley Initiates PTC Therapeutics at Equalweight With $54 Price Target, Cites 'Catalyst-Rich But Uncertain Story'
Morgan Stanley Initiates PTC Therapeutics at Equalweight With $54 Price Target, Cites 'Catalyst-Rich But Uncertain Story'
MT Newswires · 09/09 09:04
PTC Therapeutics' 2022 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the four recipients of its 2022 STRIVE Awards for Duchenne Muscular Dystrophy. The STRIVE program provides grants to non-profit patient advocacy organizations serving the Duchenne community. This year, ...
PR Newswire · 09/07 12:00
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
Upgrades
Benzinga · 09/01 14:33
More
About PTCT
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).

Webull offers kinds of PTC Therapeutics, Inc. stock information, including NASDAQ:PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.